Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were randomly assigned to 1 of 4 treatment regimens: 3 groups received a blood schizonticidal dose of chloroquine followed by WR 238605: group A (n=15) received 300 mg daily for 7 days; group B (n=11), 500 mg daily for 3 days, repeated 1 week after the initial dose; group C (n=9), 1 dose of 500 mg. A fourth group (D; n=9) received chloroquine only. Among patients who completed 2-6 months of follow-up (n=23), there was 1 relapse in group B (day 120) and 1 in group C (day 112). Among patients treated with chloroquine only, there were 4 relapses (days 40, 43, 49, and 84). WR 238605 was safe, well tolerated, and effective in preventing P. vivax relapse.
Walsh
D S
DS
Department of Immunology, US Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. ltc_douglas_walsh@wrsmtp-ccmail.army.mil
Looareesuwan
S
S
Wilairatana
P
P
Heppner
D G
DG
Tang
D B
DB
Brewer
T G
TG
Chokejindachai
W
W
Viriyavejakul
P
P
Kyle
D E
DE
Milhous
W K
WK
Schuster
B G
BG
Horton
J
J
Braitman
D J
DJ
Brueckner
R P
RP
D000293:Adolescent; D000328:Adult; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016780:Malaria, Vivax / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D011446:Prospective Studies; D012008:Recurrence; D013785:Thailand
D000634:Aminoquinolines; D000962:Antimalarials; C055852:tafenoquine; D002738:Chloroquine